Following the results of January 28, worldwide, the Johnson & Johnson vaccine has shown an effectiveness of 66% against mild to severe Covid-19 and a success rate of 85% against severe forms of the disease. Confirmation from Professor Glenda Gray, principal investigator for the South African part of the trials, who argued that the results of the phase 3 trial of the Johnson & Johnson vaccine are good news for South Africans who are watching the end of a second deadly wave of Covid-19. She added: “This is great news and shows that we are protected against severe Covid. The vaccine can prevent death and hospitalization, and it reduces the burden of disease ”.
